EP2015772A2 - Agent de traitement de pathologies malignes - Google Patents
Agent de traitement de pathologies malignesInfo
- Publication number
- EP2015772A2 EP2015772A2 EP07724827A EP07724827A EP2015772A2 EP 2015772 A2 EP2015772 A2 EP 2015772A2 EP 07724827 A EP07724827 A EP 07724827A EP 07724827 A EP07724827 A EP 07724827A EP 2015772 A2 EP2015772 A2 EP 2015772A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- bat3
- tumor
- cells
- protein
- malignant diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 23
- 230000003211 malignant effect Effects 0.000 title claims abstract description 21
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 28
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 27
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 20
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims abstract description 19
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 8
- 238000009169 immunotherapy Methods 0.000 claims abstract description 8
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract description 7
- 239000000427 antigen Substances 0.000 claims abstract description 7
- 102000036639 antigens Human genes 0.000 claims abstract description 7
- 108091007433 antigens Proteins 0.000 claims abstract description 7
- 230000005975 antitumor immune response Effects 0.000 claims abstract description 7
- 238000001727 in vivo Methods 0.000 claims abstract description 6
- 239000012876 carrier material Substances 0.000 claims abstract description 5
- 102000002752 Natural Cytotoxicity Triggering Receptor 3 Human genes 0.000 claims abstract description 4
- 101000697493 Homo sapiens Large proline-rich protein BAG6 Proteins 0.000 claims abstract 19
- 102100028047 Large proline-rich protein BAG6 Human genes 0.000 claims abstract 19
- 239000002299 complementary DNA Substances 0.000 claims abstract 2
- 239000012634 fragment Substances 0.000 claims abstract 2
- 239000004480 active ingredient Substances 0.000 claims description 13
- 238000002560 therapeutic procedure Methods 0.000 claims description 13
- 230000004913 activation Effects 0.000 claims description 12
- 230000001413 cellular effect Effects 0.000 claims description 9
- 230000002018 overexpression Effects 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 9
- 102100035721 Syndecan-1 Human genes 0.000 claims description 7
- 238000012546 transfer Methods 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 5
- 230000000638 stimulation Effects 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 230000003013 cytotoxicity Effects 0.000 claims description 4
- 231100000135 cytotoxicity Toxicity 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 108700005077 Viral Genes Proteins 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 8
- 238000009472 formulation Methods 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 abstract description 30
- 108090000623 proteins and genes Proteins 0.000 abstract description 19
- 102000004169 proteins and genes Human genes 0.000 abstract description 17
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 abstract description 16
- 230000003213 activating effect Effects 0.000 abstract description 6
- 230000004927 fusion Effects 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 4
- 230000004936 stimulating effect Effects 0.000 abstract description 2
- 102000042628 natural cytotoxicity receptor (NCR) family Human genes 0.000 abstract 1
- 108091053394 natural cytotoxicity receptor (NCR) family Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 25
- 239000003446 ligand Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 6
- 229910052693 Europium Inorganic materials 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000007999 Nuclear Proteins Human genes 0.000 description 3
- 108010089610 Nuclear Proteins Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000005859 cell recognition Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 210000001808 exosome Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101000607320 Homo sapiens UL16-binding protein 2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 description 1
- 102000000812 NK Cell Lectin-Like Receptor Subfamily K Human genes 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102000019361 Syndecan Human genes 0.000 description 1
- 108050006774 Syndecan Proteins 0.000 description 1
- 108090000058 Syndecan-1 Proteins 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 102100039989 UL16-binding protein 2 Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000043557 human IFNG Human genes 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011293 immunotherapeutic strategy Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/56—Kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Agent de traitement de pathologies tumorales, telles que par exemple le myélome multiple, qui agit sur les cellules NK par l'activation d'une réponse immunitaire anti-tumorale aptès stimulation du récepteur NKp30 et des récepteurs de cytotoxicité naturelle (NCR). Il s'agit d'une quantité physiologiquement efficace de la protéine BAT3, BAT3/antiCD138 ou d'anticorps sécifiques de BAT3 ou de dérivés de ces produits, dans un excipient acceptable. En outre, la présente invention peut également être utilisée pour le traitement de tumeurs à négativité CD138 selon le principe identique de la protéine BAT3/antiCD138. A cet effet, la fraction antiCD138 avec un fragment d'anticorps est échangée contre un antigène tumoral quelconque et l'agent correspondant est utilisé pour la thérapie de tumeurs qui expriment cet antigène tumoral. La présente invention concerne encore l'utilisation de protéine BAT3 de recombinaison ou d'un fragment de BAT3 sans fraction de fusion basée sur les anticorps pour traiter des pathologies malignes par l'activation de NKp30 et NCR sur des cellules NK. La présente invention concerne enfin l'utilisation de l'ADNc BAT3 pour l'introduction in vivo et / ou ex vivo de BAT3 dans des cellules tumorales qui entraîne une meilleure reconnaissance par les cellules NK, pour la térapie immunitaire de pathologies malignes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006020317 | 2006-05-03 | ||
| DE102006028893 | 2006-06-21 | ||
| PCT/EP2007/003901 WO2007144046A2 (fr) | 2006-05-03 | 2007-05-03 | Agent de traitement de pathologies malignes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2015772A2 true EP2015772A2 (fr) | 2009-01-21 |
Family
ID=38523448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP07724827A Withdrawn EP2015772A2 (fr) | 2006-05-03 | 2007-05-03 | Agent de traitement de pathologies malignes |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20100291105A1 (fr) |
| EP (1) | EP2015772A2 (fr) |
| WO (1) | WO2007144046A2 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2238169A1 (fr) | 2007-12-26 | 2010-10-13 | Biotest AG | Procédé permettant de réduire les effets secondaires cytotoxiques et d'améliorer l'efficacité des immunoconjugués |
| CA2710483C (fr) * | 2007-12-26 | 2018-05-08 | Biotest Ag | Procedes et agents permettant d'ameliorer le ciblage de cellules tumorales exprimant cd138 |
| DK2242772T3 (en) | 2007-12-26 | 2015-01-05 | Biotest Ag | Immunoconjugates that targets CD138, and uses thereof |
| CN101952315B (zh) | 2007-12-26 | 2015-04-01 | 生物测试股份公司 | 靶向cd138的试剂及其应用 |
| KR101725170B1 (ko) | 2009-05-06 | 2017-04-10 | 바이오테스트 아게 | Ｃｄ１３８을 표적으로 하는 면역접합체의 용도 |
| AU2013201618B2 (en) * | 2009-05-06 | 2016-06-02 | Biotest Ag | Uses of immunoconjugates targeting CD138 |
| RU2632108C2 (ru) | 2011-12-08 | 2017-10-02 | Биотест Аг | Применения иммуноконъюгатов, мишенью которых является cd138 |
| GB201216002D0 (en) * | 2012-09-07 | 2012-10-24 | Deutsches Rheuma Forschungszentrum Berlin Drfz | Compositions adn methods |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1140973A4 (fr) * | 1998-12-22 | 2002-10-30 | Myriad Genetics Inc | Interactions proteine-proteine dans les troubles neurodegeneratifs |
| US20050112118A1 (en) * | 1999-12-02 | 2005-05-26 | Myriad Genetics, Incorporated | Compositions and methods for treating inflammatory disorders |
-
2007
- 2007-05-03 US US12/594,787 patent/US20100291105A1/en not_active Abandoned
- 2007-05-03 WO PCT/EP2007/003901 patent/WO2007144046A2/fr active Application Filing
- 2007-05-03 EP EP07724827A patent/EP2015772A2/fr not_active Withdrawn
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2007144046A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007144046A2 (fr) | 2007-12-21 |
| WO2007144046A3 (fr) | 2008-04-03 |
| US20100291105A1 (en) | 2010-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2015772A2 (fr) | Agent de traitement de pathologies malignes | |
| DE69637332T2 (de) | Kombinierung von PDGF, KGF, IGF und IGFBP für Wundheilung | |
| DE69332907T2 (de) | Flk-1 ist ein rezeptor für den wachstumsfaktor der vaskularen endothelzellen | |
| DE60034579T3 (de) | Baff rezeptor (bcma), ein immunoregulatorisches mittel | |
| Renner et al. | Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells | |
| DE60122337T2 (de) | Verwendung von taci als antitumormittel | |
| DE69333027T2 (de) | Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält | |
| DE69731834T2 (de) | Agouti verwandtes gen | |
| DE69534962T3 (de) | Htk-ligand | |
| DE60034781T2 (de) | In vitro verfahren zur induzierung der regulierten pankreatische-hormon produktion in nicht-pankreatischen inselngeweben, damit verbundene pharmazeutische zusammenseztzungen | |
| DE4118120A1 (de) | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung | |
| DE69926764T2 (de) | Methoden zur bestimmung von komponenten zur modulation des körpergewichts | |
| DE102013019352A1 (de) | Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort | |
| EP1727833A1 (fr) | Polypeptides recombines des membres de la famille des ligands tnf et leur utilisation | |
| DE69836963T2 (de) | PGC-1, EIN NEUARTIGER PPAR-gamma-KOAKTIVATOR AUS BRAUNEM FETTGEWEBE | |
| DE69837085T3 (de) | Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen | |
| EP0888384A2 (fr) | Conjugue pour influer sur les interactions entre des proteines | |
| DE69535713T2 (de) | Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette | |
| DE19882755B4 (de) | Ein Fusionsprotein des hEGF und des humanen Angiogenins und ein Verfahren zu dessen Herstellung | |
| DE69631837T2 (de) | FCepsilon-PE, EIN CHIMÄRES PROTEIN FÜR DIE GEZIELTE BEHANDLUNG ALLERGISCHER REAKTIONEN, EINE METHODE FÜR DESSEN HERSTELLUNG UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN DIE DAS PROTEIN BEINHALTEN | |
| DE69912743T2 (de) | Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)-aktivierungsweges | |
| DE69813204T2 (de) | Materialen und verfahren im zusammenhang mit der inhibierung der wechselwirkung der p53 und mdm2 | |
| WO2001002556A2 (fr) | Agents pour le diagnostic, le pronostic et la therapie relatifs a des maladies malignes | |
| DE102008014880A1 (de) | Antientzündliches Polypeptid | |
| EP1383872B1 (fr) | Lignee cellulaire yt genetiquement modifiee et son utilisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20081203 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
| 17Q | First examination report despatched |
Effective date: 20090416 |
|
| R17C | First examination report despatched (corrected) |
Effective date: 20090511 |
|
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20121201 |